Cargando…
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119245/ https://www.ncbi.nlm.nih.gov/pubmed/34475521 http://dx.doi.org/10.1038/s41375-021-01396-x |
| _version_ | 1784710664603828224 |
|---|---|
| author | Cervantes, Francisco Ross, David M. Radinoff, Atanas Palandri, Francesca Myasnikov, Alexandr Vannucchi, Alessandro M. Zachee, Pierre Gisslinger, Heinz Komatsu, Norio Foltz, Lynda Mannelli, Francesco Passamonti, Francesco Gilotti, Geralyn Sadek, Islam Tiwari, Ranjan Zor, Evren Al-Ali, Haifa Kathrin |
| author_facet | Cervantes, Francisco Ross, David M. Radinoff, Atanas Palandri, Francesca Myasnikov, Alexandr Vannucchi, Alessandro M. Zachee, Pierre Gisslinger, Heinz Komatsu, Norio Foltz, Lynda Mannelli, Francesco Passamonti, Francesco Gilotti, Geralyn Sadek, Islam Tiwari, Ranjan Zor, Evren Al-Ali, Haifa Kathrin |
| author_sort | Cervantes, Francisco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9119245 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91192452022-05-20 Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study Cervantes, Francisco Ross, David M. Radinoff, Atanas Palandri, Francesca Myasnikov, Alexandr Vannucchi, Alessandro M. Zachee, Pierre Gisslinger, Heinz Komatsu, Norio Foltz, Lynda Mannelli, Francesco Passamonti, Francesco Gilotti, Geralyn Sadek, Islam Tiwari, Ranjan Zor, Evren Al-Ali, Haifa Kathrin Leukemia Correction Nature Publishing Group UK 2021-09-02 2021 /pmc/articles/PMC9119245/ /pubmed/34475521 http://dx.doi.org/10.1038/s41375-021-01396-x Text en © The Author(s), under exclusive licence to Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Cervantes, Francisco Ross, David M. Radinoff, Atanas Palandri, Francesca Myasnikov, Alexandr Vannucchi, Alessandro M. Zachee, Pierre Gisslinger, Heinz Komatsu, Norio Foltz, Lynda Mannelli, Francesco Passamonti, Francesco Gilotti, Geralyn Sadek, Islam Tiwari, Ranjan Zor, Evren Al-Ali, Haifa Kathrin Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title | Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title_full | Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title_fullStr | Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title_full_unstemmed | Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title_short | Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study |
| title_sort | correction: efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the realise phase 2 study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119245/ https://www.ncbi.nlm.nih.gov/pubmed/34475521 http://dx.doi.org/10.1038/s41375-021-01396-x |
| work_keys_str_mv | AT cervantesfrancisco correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT rossdavidm correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT radinoffatanas correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT palandrifrancesca correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT myasnikovalexandr correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT vannucchialessandrom correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT zacheepierre correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT gisslingerheinz correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT komatsunorio correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT foltzlynda correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT mannellifrancesco correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT passamontifrancesco correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT gilottigeralyn correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT sadekislam correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT tiwariranjan correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT zorevren correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study AT alalihaifakathrin correctionefficacyandsafetyofanoveldosingstrategyforruxolitinibinthetreatmentofpatientswithmyelofibrosisandanemiatherealisephase2study |